2020
DOI: 10.20945/2359-3997000000251
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective: To evaluate the use of metformin for preventing cesarean deliveries and large-forgestational-age (LGA) newborn (NB) outcomes in non-diabetic obese pregnant women. Subjects and methods: This is a randomized clinical trial with obese pregnant women, divided into 2 groups: metformin group and control group, with followed-up prenatal routine. The gestational age of participants was less than or equal to 20 weeks and were monitored throughout entire prenatal period. For outcomes of delivery and LGA newbo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 13 publications
(10 citation statements)
references
References 33 publications
0
10
0
Order By: Relevance
“…Sixteen RCTs [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] were included in the analyses (Figure 1, Table 1, Table S1), and 51 were excluded (Table S2). Of the included studies, six included overweight pregnant women and 15 with obesity.…”
Section: Resultsmentioning
confidence: 99%
“…Sixteen RCTs [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] were included in the analyses (Figure 1, Table 1, Table S1), and 51 were excluded (Table S2). Of the included studies, six included overweight pregnant women and 15 with obesity.…”
Section: Resultsmentioning
confidence: 99%
“…For example, in obese pregnant women, an intervention that consisted of both dietary advice and an exercise intervention can reduce gestational weight gain (37). In addition, others have investigated the benefit of therapeutics such as metformin in reducing the adverse outcomes associated with maternal obesity in pregnancy (81). Metformin in obese pregnant mothers reduced the need for caesarean section and preeclampsia; however, this did not reduce the risk of LGA (81).…”
Section: Potential Interventions and Therapeuticsmentioning
confidence: 99%
“…In obese pregnant women, a significant reduction in PE frequency was observed in two studies [146,147] without such effect as in the research carried out by Chiswick et al [122]. There was no reduction in the incidence of PIH in obese pregnant women under the influence of metformin, although, in all studies, its administration was started before the 20th week [122,146,147].…”
Section: Metformin In Preventing Hypertensive Disorders Of Pregnancymentioning
confidence: 81%
“…The most common comparison was the effect of metformin on the pregnancy course with the effect of insulin. Only studies in obese pregnant women or women with PCOS compared the impact of metformin to placebo or no treatment [122,[146][147][148]. The dose of metformin used was also not uniform: treatment usually started with a dose of 500 mg, which was increased at different intervals to the maximum dose of 3000 mg [147], although in most studies, the maximum dose was 2500 mg [122,143,145].…”
Section: Metformin In Preventing Hypertensive Disorders Of Pregnancymentioning
confidence: 99%